The treatment landscape of metastatic prostate cancer (mPCa) has evolved significantly over the past two decades. Despite this, the optimal therapy for patients with mPCa has not been determined. This systematic review identifies available predictive models that assess mPCa patients' response to treatment.
We critically reviewed MEDLINE and CENTRAL in December 2022 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Only quantitative studies in English were included with no time restrictions. The quality of the included studies was assessed using the PROBAST tool. Data were extracted following the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews criteria.
The search identified 616 citations, of which 15 studies were included in our review. Nine of the included studies were validated internally or externally. Only one study had a low risk of bias and a low risk concerning applicability. Many studies failed to detail model performance adequately, resulting in a high risk of bias. Where reported, the models indicated good or excellent performance.
Most of the identified predictive models require additional evaluation and validation in properly designed studies before these can be implemented in clinical practice to assist with treatment decision-making for men with mPCa.
In this review, we evaluate studies that predict which treatments will work best for which metastatic prostate cancer patients. We found that existing studies need further improvement before these can be used by health care professionals.
European urology open science. 2024 Apr 04*** epublish ***
Ailbhe Lawlor, Carol Lin, Juan Gómez Rivas, Laura Ibáñez, Pablo Abad López, Peter-Paul Willemse, Muhammad Imran Omar, Sebastiaan Remmers, Philip Cornford, Pawel Rajwa, Rossella Nicoletti, Giorgio Gandaglia, Jeremy Yuen-Chun Teoh, Jesús Moreno Sierra, Asieh Golozar, Anders Bjartell, Susan Evans-Axelsson, James N'Dow, Jihong Zong, Maria J Ribal, Monique J Roobol, Mieke Van Hemelrijck, Katharina Beyer, PIONEER Consortium
Translational Oncology and Urology Research (TOUR), King's College London, London, UK., Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands., Department of Urology, Health Research Institute, Hospital Clinico San Carlos, Madrid, Spain., Department of Urology, Hospital Universitario La Paz, Madrid, Spain., Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands., Academic Urology Unit, University of Aberdeen, Aberdeen, UK., Liverpool University Hospitals NHS Trust, Liverpool, UK., Department of Urology, Medical University of Silesia, Zabrze, Poland., Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy., Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy., S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China., OHDSI Center, Northeastern University, Boston, MA, USA., Department of Translational Medicine, Lund University, Malmö, Sweden., Bayer AB, Medical Affairs Oncology, Stockholm, Sweden., European Association of Urology, Guidelines Office, Arnhem, The Netherlands., Bayer Healthcare, Global Medical Affairs Oncology, Whippany, NJ, USA.